Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
Clinicoeconomics and Outcomes Research : CEOR
|
June 10, 2024
Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score<sup>®</sup> Test from a US Societal Perspective
Vladislav Berdunov, Gebra Cuyun Carter, Ewan Laws, et al.
Cancer Investigation
|
December 13, 2006
Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma
Steven M Grunberg, Martin H Weiss, Christy A Russell, et al.
Annals of Surgical Oncology
|
July 9, 2021
Discordance in Oncotype DX Breast Recurrence Score<sup>®</sup> Results for Bilateral Breast Cancer
Joshua A Bloom, Yurie Sekigami, Rebekah Young, et al.
Journal of Surgical Oncology
|
September 20, 2016
Value of routine staging imaging studies for patients with stage III breast cancer
Caroline I Piatek, Lingyun Ji, Chandan Kaur, et al.
Breast Cancer Research and Treatment
|
April 28, 2004
A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer
Gary H Lyman, Stephanie J Green, Peter M Ravdin, et al.
Journal of the National Cancer Institute
|
February 11, 2020
Young-Onset Colon Cancer and Recurrence Risk by Gene Expression
George J Chang, Y Nancy Y You, Christy A Russell, et al.
JCO Precision Oncology
|
December 22, 2025
Concordance of Oncotype DX Breast Recurrence Score Assay Results Between Paired Core Needle Biopsy and Surgical Excision Specimens in Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative, Early-Stage Breast Cancer
Aziza Nassar, Jodi Carter, Paige Innis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 12, 2011
Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012
Georgiana K Ellis, William E Barlow, Julie R Gralow, et al.
Journal of the National Cancer Institute
|
May 19, 2021
Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer
Olga Kantor, Tari A King, Steven Shak, et al.
Breast Cancer Research and Treatment
|
April 8, 2015
Lymph node status in inflammatory breast cancer
Julie S Wecsler, Welela Tereffe, Rose C Pedersen, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
Clinicoeconomics and Outcomes Research : CEOR
|
June 10, 2024
Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score<sup>®</sup> Test from a US Societal Perspective
Vladislav Berdunov, Gebra Cuyun Carter, Ewan Laws, et al.
Cancer Investigation
|
December 13, 2006
Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma
Steven M Grunberg, Martin H Weiss, Christy A Russell, et al.
Annals of Surgical Oncology
|
July 9, 2021
Discordance in Oncotype DX Breast Recurrence Score<sup>®</sup> Results for Bilateral Breast Cancer
Joshua A Bloom, Yurie Sekigami, Rebekah Young, et al.
Journal of Surgical Oncology
|
September 20, 2016
Value of routine staging imaging studies for patients with stage III breast cancer
Caroline I Piatek, Lingyun Ji, Chandan Kaur, et al.
Breast Cancer Research and Treatment
|
April 28, 2004
A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer
Gary H Lyman, Stephanie J Green, Peter M Ravdin, et al.
Journal of the National Cancer Institute
|
February 11, 2020
Young-Onset Colon Cancer and Recurrence Risk by Gene Expression
George J Chang, Y Nancy Y You, Christy A Russell, et al.
JCO Precision Oncology
|
December 22, 2025
Concordance of Oncotype DX Breast Recurrence Score Assay Results Between Paired Core Needle Biopsy and Surgical Excision Specimens in Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative, Early-Stage Breast Cancer
Aziza Nassar, Jodi Carter, Paige Innis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 12, 2011
Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012
Georgiana K Ellis, William E Barlow, Julie R Gralow, et al.
Journal of the National Cancer Institute
|
May 19, 2021
Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer
Olga Kantor, Tari A King, Steven Shak, et al.
Breast Cancer Research and Treatment
|
April 8, 2015
Lymph node status in inflammatory breast cancer
Julie S Wecsler, Welela Tereffe, Rose C Pedersen, et al.
Page
of 3